文献速递血脂与心血管预防

老年人他汀类药物一级预防的指南差异与证据解读

Primary Prevention With Statins in the Elderly.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

本文针对老年人(>65岁)动脉粥样硬化性心血管疾病(ASCVD)一级预防中他汀的使用,对比了2013年以来北美和欧洲5大指南的推荐差异。作者将不同推荐置于现有证据背景下讨论,并指出在哪些情况下不确定性可能妨碍老年人他汀的合理使用。

要点

  • 5大指南对>65岁老年人他汀一级预防推荐存在明显差异。
  • 临床需结合现有证据识别不确定性场景以合理使用他汀。
  • 老年人ASCVD负担重,明确他汀一级预防策略对健康老龄化至关重要。

核心结论

  • 2013年以来5大指南对>65岁老年人他汀一级预防的推荐差异显著,需在证据背景下理解并识别不确定性场景。

研究设计与样本

  • 本文为综述性讨论,对比美国心脏病学会/美国心脏协会、英国国家卫生与临床优化研究所、加拿大心血管学会、美国预防服务工作组和欧洲心脏病学会/欧洲动脉粥样硬化学会发布的5个主要指南。

主要发现

  • 5大指南对>65岁老年人他汀一级预防的推荐存在明显差异。
  • 作者识别了不确定性可能妨碍老年人他汀合理使用的情况。

临床怎么用

  • 临床医生应了解各指南对老年人他汀一级预防推荐的差异,结合现有证据和不确定性场景个体化决策。

局限性

  • 原文未报告系统检索策略或定量证据汇总。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The burden of atherosclerotic cardiovascular disease (ASCVD) in high-income countries is mostly borne by the elderly. With increasing life expectancy, clear guidance on sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population. Since 2013, 5 major North American and European guidelines on statin use in primary prevention of ASCVD have been released by the American College of Cardiology/American Heart Association, the UK National Institute for Health and Care Excellence, the Canadian Cardiovascular Society, U.S. Preventive Services Task Force, and the European Society of Cardiology/European Atherosclerosis Society. Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. The authors discuss the discrepant recommendations, place them into the context of available evidence, and identify circumstances in which uncertainty may hamper the appropriate use of statins in the elderly.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. J Am Coll Cardiol. 2018. PMID: 29301631. doi:10.1016/j.jacc.2017.10.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。